Abelin and co-authors suggested that, within tumour microenvironment (TME), CD4+ Th cells are mainly activated by resident APCs, which present neoantigens, derived from endocytosed tumour proteins, in the context of MHC II. The gene discussed is CD4; the disease is neoplasm.